Takeda
-
Takeda deploys Weave Bio’s AI Regulatory Platform across 14 active global drug programs
The collaboration combines Weave Bio’s artificial intelligence tools with Takeda’s regulatory expertise to simplify and speed up activities involved in preparing submissions and responding to questions from health authorities.
-
Takeda secures FDA approval for oral orexin agonist Orzeyful in US market
The approval expands Orzeyful’s commercial reach following its authorization in China in July 2026, marking another milestone in Takeda’s global launch strategy.
-
Takeda to invest US$30M in Indonesia’s first biolife plasma network
The approval authorises the company to collect plasma in Indonesia and process it through its global manufacturing network while the country develops its own plasma infrastructure.
-
Insilico Medicine signs strategic US$600M AI drug discovery agreement with Takeda
Under the collaboration, Insilico Medicine will use its proprietary Pharma.AI platform to identify and optimise drug candidates that meet predefined scientific and early development criteria.
-
Egypt strengthens pharmaceutical research partnership with Takeda to boost healthcare innovation
The meeting represents part of the Egyptian Drug Authority’s ongoing efforts to engage with leading international pharmaceutical companies and promote strategic partnerships that support industry development.
-
Takeda-Innovent closes USD11.4B immuno-oncology partnership
The two pharmaceutical giants originally signed the agreement in October 2025, establishing a framework centered on bispecific antibodies and ADCs.